- Home
- WIMI vs MAIA Comparison
WIMI vs MAIA Comparison
Compare WIMI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIMI
- MAIA
- Stock Information
- Founded
- WIMI 2015
- MAIA 2018
- Country
- WIMI China
- MAIA United States
- Employees
- WIMI N/A
- MAIA N/A
- Industry
- WIMI Computer Software: Prepackaged Software
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- WIMI Technology
- MAIA Health Care
- Exchange
- WIMI Nasdaq
- MAIA Nasdaq
- Market Cap
- WIMI 51.6M
- MAIA 44.9M
- IPO Year
- WIMI 2020
- MAIA 2022
- Fundamental
- Price
- WIMI $3.08
- MAIA $1.08
- Analyst Decision
- WIMI
- MAIA
- Analyst Count
- WIMI 0
- MAIA 0
- Target Price
- WIMI N/A
- MAIA N/A
- AVG Volume (30 Days)
- WIMI 209.6K
- MAIA 769.0K
- Earning Date
- WIMI 01-01-0001
- MAIA 11-07-2025
- Dividend Yield
- WIMI N/A
- MAIA N/A
- EPS Growth
- WIMI N/A
- MAIA N/A
- EPS
- WIMI 1.43
- MAIA N/A
- Revenue
- WIMI $61,329,146.00
- MAIA N/A
- Revenue This Year
- WIMI N/A
- MAIA N/A
- Revenue Next Year
- WIMI N/A
- MAIA N/A
- P/E Ratio
- WIMI $2.45
- MAIA N/A
- Revenue Growth
- WIMI N/A
- MAIA N/A
- 52 Week Low
- WIMI $2.24
- MAIA $1.05
- 52 Week High
- WIMI $29.20
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- WIMI 29.62
- MAIA 31.36
- Support Level
- WIMI $3.39
- MAIA $1.05
- Resistance Level
- WIMI $3.57
- MAIA $1.35
- Average True Range (ATR)
- WIMI 0.22
- MAIA 0.10
- MACD
- WIMI -0.08
- MAIA -0.03
- Stochastic Oscillator
- WIMI 1.82
- MAIA 5.29
About WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.